FDA approves MAMMOMAT Revelation for breast biopsies- Siemens Healthineers.

The FDA has cleared MAMMOMAT Revelation, a premium mammography platform from Siemens Healthineers with the new InSpect integrated specimen imaging tool and the new HD Breast Biopsy solution for one-click targeting of suspicious areas. These and other features are designed to expand precision medicine and improve the patient experience.

MAMMOMAT Revelation�s InSpect integrated specimen imaging tool permits imaging and real-time review of biopsy samples at the workstation. This tool improves biopsy workflow, shortens compression time, and reduces patient discomfort. HD Breast Tomosynthesis offers the widest image acquisition angle available at 50 degrees. The wide angle delivers the industry�s highest depth resolution for better separation of overlapping breast tissue, providing high-quality 3D images for improved diagnostic confidence and earlier lesion detection. This technology is the basis for MAMMOMAT Revelation�s HD Breast Biopsy solution, which enables one-click targeting of suspicious areas with a +/- 1mm accuracy.

Comment: Nearly half of all women in the United States who receive mammograms have dense breasts, complicating efforts to identify breast lesions. Typically, the radiologist assesses breast density visually after the patient has left the facility. MAMMOMAT Revelation is the first platform to offer automated breast density measurement during the mammogram for immediate, personalized risk stratification, and more personalized care.

Comment;Mammomat Revelationt is the first mammography system capable of automatic breast density measurement during the exam itself, as opposed to during review of the images.